AU2008240181B2 - Tuberculosis vaccine and method of using same - Google Patents

Tuberculosis vaccine and method of using same Download PDF

Info

Publication number
AU2008240181B2
AU2008240181B2 AU2008240181A AU2008240181A AU2008240181B2 AU 2008240181 B2 AU2008240181 B2 AU 2008240181B2 AU 2008240181 A AU2008240181 A AU 2008240181A AU 2008240181 A AU2008240181 A AU 2008240181A AU 2008240181 B2 AU2008240181 B2 AU 2008240181B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
mycobacterium
inactivated
mtb
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008240181A
Other languages
English (en)
Other versions
AU2008240181A1 (en
Inventor
Jason Fisher
Jennifer Lighter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2008240181A1 publication Critical patent/AU2008240181A1/en
Application granted granted Critical
Publication of AU2008240181B2 publication Critical patent/AU2008240181B2/en
Priority to AU2014201218A priority Critical patent/AU2014201218A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008240181A 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same Ceased AU2008240181B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201218A AU2014201218A1 (en) 2007-04-12 2014-03-05 Tuberculosis vaccine and method of using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92330107P 2007-04-12 2007-04-12
US60/923,301 2007-04-12
PCT/US2008/060065 WO2008128065A2 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201218A Division AU2014201218A1 (en) 2007-04-12 2014-03-05 Tuberculosis vaccine and method of using same

Publications (2)

Publication Number Publication Date
AU2008240181A1 AU2008240181A1 (en) 2008-10-23
AU2008240181B2 true AU2008240181B2 (en) 2014-01-09

Family

ID=39523390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008240181A Ceased AU2008240181B2 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Country Status (14)

Country Link
US (3) US8394389B2 (enExample)
EP (1) EP2144626B8 (enExample)
JP (2) JP5713672B2 (enExample)
AU (1) AU2008240181B2 (enExample)
CA (1) CA2682870C (enExample)
CY (1) CY1117290T1 (enExample)
DK (1) DK2144626T3 (enExample)
ES (1) ES2531018T3 (enExample)
HR (1) HRP20150177T1 (enExample)
HU (1) HUE024427T2 (enExample)
PL (1) PL2144626T3 (enExample)
PT (1) PT2144626E (enExample)
SI (1) SI2144626T1 (enExample)
WO (1) WO2008128065A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150177T1 (hr) 2007-04-12 2015-04-10 Mico Bio, Inc. Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva
ES2606511T3 (es) 2011-04-06 2017-03-24 Biovaxim Limited Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
BR112013026929A2 (pt) * 2011-04-20 2016-12-27 Mico Bio Inc composição e método para intensificação de uma resposta imune
ES2438690B1 (es) * 2012-06-15 2015-01-16 Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis
WO2014001571A1 (en) * 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
KR101615186B1 (ko) 2014-03-07 2016-04-25 연세대학교 산학협력단 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
CN108743931B (zh) * 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
ES2962407T3 (es) 2018-12-04 2024-03-18 Sabiotec Spin Off S L Inmunoestimulante para su uso contra patógenos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047225A2 (en) * 1999-02-12 2000-08-17 Eurocine Ab Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4724114A (en) 1984-04-23 1988-02-09 Kimberly-Clark Corporation Selective layering of superabsorbents in meltblown substrates
CN1612753A (zh) * 2001-11-14 2005-05-04 诺瓦瓦克斯有限公司 分枝杆菌疫苗
WO2003075824A2 (en) 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Process of manufacturing pharmaceutical composition useful for management of tuberculosis
AU2006261445B2 (en) * 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HRP20150177T1 (hr) 2007-04-12 2015-04-10 Mico Bio, Inc. Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047225A2 (en) * 1999-02-12 2000-08-17 Eurocine Ab Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Bahr G.M et al. 'Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae' Tubercle (1990) vol 71, pages 259-266 *
Carpenter, C.M, et al, 'Preliminary report on vaccines prepared from gamma-irradiated Mycobacterium Tuberculosis and Brucella Suis' The American Review of Tuberculosis and Pulmonary Diseases, 1959, vol 79, No 3, pages 374- 377 *
Giri, P.K., et al., 'Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis', FEMS Immunology and Medical Microbiology, 2005, Vol 45, pages 87-93 *
Haile, M. et al., 'Immunization with heat killed Mycobacterium bovis bacille Calmette- Guerin (BCG) in EurocrineTM L3 adjuvant protects against tuberculosis.' Vaccine. 2004, vol. 22, pages 1498-1508 *
Nishihara, H, et al, 'Immunogenicity of gamma-irradiated Mycobacterium Tuberculosis H37Rv (GIV) in mice' American Review of Respiratory Disease 1963, vol 88, No6, pages 827-832 *
Stanford J.L et al. 'Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis' Tubercle (1990) vol 71, pages 87-93 *

Also Published As

Publication number Publication date
EP2144626B8 (en) 2015-02-18
SI2144626T1 (sl) 2015-04-30
US8394389B2 (en) 2013-03-12
CA2682870C (en) 2016-08-09
US20150258187A1 (en) 2015-09-17
US9636391B2 (en) 2017-05-02
JP2010523711A (ja) 2010-07-15
PT2144626E (pt) 2015-03-03
EP2144626A2 (en) 2010-01-20
US20130273110A1 (en) 2013-10-17
WO2008128065A3 (en) 2008-12-18
US20100112007A1 (en) 2010-05-06
WO2008128065A2 (en) 2008-10-23
CA2682870A1 (en) 2008-10-23
HRP20150177T1 (hr) 2015-04-10
US8932608B2 (en) 2015-01-13
ES2531018T3 (es) 2015-03-09
AU2008240181A1 (en) 2008-10-23
HUE024427T2 (en) 2016-01-28
JP2015038130A (ja) 2015-02-26
PL2144626T3 (pl) 2015-09-30
JP5713672B2 (ja) 2015-05-07
DK2144626T3 (en) 2015-02-09
CY1117290T1 (el) 2017-04-26
EP2144626B1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
AU2008240181B2 (en) Tuberculosis vaccine and method of using same
Gong et al. The current status, challenges, and future developments of new tuberculosis vaccines
Salvin et al. Brief communication: tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity
JP2010523711A5 (enExample)
Tyne et al. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines
Stylianou et al. Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
RU2526910C2 (ru) Профилактическая вакцина от туберкулеза
Liu et al. Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design
JP6655549B2 (ja) 免疫応答を誘導するための新規方法
Giri et al. Is intranasal vaccination a feasible solution for tuberculosis?
Carpenter et al. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu
ES2335177B1 (es) Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
DK2341928T3 (en) MYCOBACTERIUM TUBERCULOSIS VACCINE
CN104582721B (zh) 用于防止结核病的口服灭活分枝杆菌
AU2014201218A1 (en) Tuberculosis vaccine and method of using same
Garcia-Contreras et al. Inhaled vaccines for the prevention of tuberculosis
Neustrup Nanoparticles and microfluidics for future tuberculosis accines
KR20250131865A (ko) 면역증강제를 포함하는 결핵 예방용 mRNA 백신 조성물
Chuang et al. Albumin Fusion with Granulocyte-Macrophage Colony-Stimulating Factor Acts as an in Situ Therapeutic Vaccine Against Chronic Tuberculosis in Mice
HK1138786B (en) Prophylactic tuberculosis vaccine
Xing BCG and New Tuberculosis Vaccines
ZHAO Primary Study on the Action of Genome DNA of Mycobacterium Bovis-Bacille Calmette-Guerin for Macrophage Activation in Mice
OA16638A (en) Composition and method for enhancing an immune response.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired